%0 Journal Article
%T A true theranostic pair – 44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer
%W https://pubmed.ncbi.nlm.nih.gov/41217470/
%U https://doi.org/10.1007/s00259-025-07651-y
%X This study investigates the theranostic potential of a 44/47Sc-labeled antagonist targeting the gastrin-releasing peptide receptor (GRPR) in prostate and breast tumors.
%G en
%J European Journal of Nuclear Medicine and Molecular Imaging
%A Kumar, Naveen
%A Bilinska, Adrianna
%A Menéndez, Elena
%A Läppchen, Tilman
%A Moon, Euy Sung
%A Zoltowska, Malgorzata
%A Pawlak, Dariusz
%A Cieszykowska, Izabela
%A Mikolajczak, Renata
%A Rösch, Frank
%A Rominger, Axel
%A Gourni, Eleni
%D 2025-11-11
%K 44/47Sc
Everolimus
Fractionated dose
GRPR antagonist
mTOR inhibitor
user-project